Last 33 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -115.60 | — | — | — | — | — | 10.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.17 | 19.61 | 8.25 | 4.51 | 3.12 | 2.46 | 2.08 | 1.73 | 2.65 | 4.49 | 3.81 | 7.94 | 9.02 | 7.90 | 11.10 | 12.01 | 6.69 | 6.20 | 11.21 | 18.76 | 29.03 |
| — | +696.7% | +295.7% | +161.3% | +18.0% | -45.2% | -45.3% | -78.3% | -70.7% | -43.1% | -65.6% | -33.8% | +34.7% | +27.5% | -1.0% | -36.0% | -77.0% | -80.8% | -75.9% | -59.6% | -14.3% | |
| P/B Ratio | 9.29 | 14.10 | 6.04 | 3.34 | 2.60 | 1.87 | 1.86 | 1.51 | 2.46 | 3.77 | 3.23 | 6.23 | 8.95 | 6.52 | 8.21 | 8.04 | 5.19 | 4.19 | 6.56 | 10.65 | 20.39 |
| — | +654.8% | +223.8% | +120.9% | +5.9% | -50.5% | -42.2% | -75.7% | -72.5% | -42.1% | -60.7% | -22.5% | +72.5% | +55.6% | +25.2% | -24.5% | -74.5% | -79.2% | -76.1% | -59.3% | -0.9% | |
| P/FCF | 80.26 | 198.82 | 80.98 | 27.77 | 13.29 | 8.62 | 22.35 | 8.24 | — | 38.39 | 161.37 | — | 74.36 | — | — | — | — | — | — | — | — |
| — | +2205.3% | +262.4% | +236.8% | — | -77.5% | -86.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 7.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 8.54 | — | 7.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.1% | 75.0% | 74.5% | 70.4% | 68.1% | 67.3% | 72.3% | 68.1% | 67.2% | 70.2% | 68.1% | 65.9% | 62.9% | 62.2% | 67.8% | 73.3% | 76.4% | 76.8% | 75.8% | 77.7% | 80.8% |
| — | +11.3% | +3.0% | +3.4% | +1.3% | -4.0% | +6.3% | +3.3% | +6.8% | +12.8% | +0.3% | -10.1% | -17.7% | -19.1% | -10.5% | -5.8% | -5.4% | -4.5% | -20.8% | -7.3% | -2.9% | |
| Operating Margin | -17.2% | -10.7% | -12.9% | -11.3% | -11.8% | -21.6% | 17.4% | -25.4% | -30.2% | -27.4% | -27.3% | -43.6% | -30.0% | -61.7% | -43.2% | -38.7% | -14.8% | -30.5% | -55.1% | -36.5% | -11.0% |
| — | +50.7% | -174.3% | +55.5% | +61.0% | +20.9% | +163.9% | +41.8% | -0.7% | +55.7% | +36.8% | -12.7% | -102.9% | -102.2% | +21.6% | -6.2% | -34.0% | -140.8% | -517.7% | -277.6% | +97.0% | |
| Net Margin | -6.8% | -12.9% | -11.9% | -8.9% | -9.8% | -18.4% | 20.0% | -22.2% | -29.7% | -23.6% | -24.8% | -42.5% | -26.6% | -60.5% | -42.5% | -37.8% | -11.0% | -32.0% | -56.2% | -37.0% | -12.9% |
| — | +30.1% | -159.4% | +59.7% | +67.1% | +21.8% | +180.7% | +47.8% | -11.7% | +61.0% | +41.8% | -12.5% | -141.5% | -89.3% | +24.4% | -2.0% | +14.3% | -133.3% | -489.5% | -239.4% | +96.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.8% | -2.3% | -2.2% | -1.7% | -2.1% | -3.5% | 4.7% | -4.8% | -6.8% | -4.9% | -5.3% | -8.2% | -6.6% | -12.1% | -7.8% | -6.3% | -2.2% | -5.4% | -8.1% | -5.2% | -2.3% |
| — | +33.8% | -146.9% | +65.5% | +70.0% | +28.7% | +188.8% | +41.0% | -3.9% | +59.1% | +32.9% | -30.1% | -202.6% | -124.8% | +3.5% | -20.8% | +4.6% | -148.1% | -463.7% | -237.2% | +95.7% | |
| ROA | -4.4% | -1.9% | -1.8% | -1.3% | -1.6% | -2.7% | 3.7% | -3.8% | -5.3% | -3.8% | -4.1% | -6.4% | -5.1% | -9.6% | -6.2% | -5.0% | -1.7% | -4.2% | -6.4% | -4.2% | -1.8% |
| — | +32.2% | -147.8% | +65.3% | +70.3% | +28.5% | +189.6% | +40.6% | -3.2% | +60.1% | +34.3% | -27.8% | -200.9% | -128.7% | +3.1% | -18.4% | +7.4% | -140.5% | -461.9% | -242.0% | +95.6% | |
| ROIC | -17.9% | -3.1% | -3.6% | -2.9% | -2.9% | -4.9% | 5.2% | -6.9% | -8.7% | -7.4% | -7.0% | -9.9% | -8.2% | -12.9% | -8.3% | -6.2% | -2.6% | -4.8% | -7.9% | -6.9% | -4.0% |
| — | +38.3% | -170.1% | +58.0% | +66.2% | +32.9% | +173.6% | +30.6% | -6.1% | +43.0% | +15.6% | -59.0% | -212.2% | -168.7% | -6.1% | +9.8% | +34.5% | -3.8% | -124.0% | -55.9% | +98.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.09 | 0.10 | 0.10 | 0.20 | 0.21 | 0.11 | 0.11 | 0.12 | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.12 | 0.12 | 0.13 | 0.13 | 0.10 |
| — | -56.6% | -14.9% | -11.8% | +70.3% | +75.2% | -9.2% | -11.7% | -9.6% | -10.1% | -1.6% | +0.8% | +9.0% | +6.5% | -0.6% | +1.4% | +17.8% | +23.8% | +40.0% | +30.2% | +17.7% | |
| Debt / EBITDA | — | — | — | — | — | — | 2.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.46 | 5.12 | 5.69 | 5.90 | 4.46 | 4.48 | 5.84 | 5.37 | 4.97 | 4.90 | 5.22 | 5.22 | 4.69 | 5.37 | 5.94 | 5.37 | 4.85 | 4.96 | 5.65 | 7.38 | 6.77 |
| — | +14.3% | -2.6% | +9.7% | -10.2% | -8.6% | +12.0% | +3.0% | +6.0% | -8.8% | -12.2% | -2.9% | -3.3% | +8.2% | +5.2% | -27.2% | -28.4% | -33.1% | -15.6% | +19.4% | +3.3% | |
| Quick Ratio | 4.09 | 4.66 | 5.25 | 5.42 | 4.09 | 4.06 | 5.23 | 4.68 | 4.26 | 4.12 | 4.42 | 4.45 | 4.11 | 4.60 | 5.09 | 4.64 | 4.23 | 4.34 | 5.05 | 6.71 | 6.23 |
| — | +14.8% | +0.4% | +15.9% | -3.9% | -1.6% | +18.2% | +5.2% | +3.7% | -10.3% | -13.1% | -4.1% | -2.8% | +5.9% | +0.8% | -30.9% | -32.2% | -37.1% | -19.9% | +14.4% | -1.1% | |
| Interest Coverage | — | — | — | — | — | -9400.67 | 12333.33 | — | — | -17218.00 | -37078.00 | -57802.00 | -5823.75 | -91743.00 | -12152.40 | -2612.37 | -130.29 | -350.18 | -584.61 | -324.73 | -72.70 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TXG stock.
10x Genomics, Inc.'s current P/E is -115.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
10x Genomics, Inc.'s current operating margin is -17.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking 10x Genomics, Inc.'s business trajectory between earnings reports.